SCG162

N/A

Report date: 2024/07/24 10:45:44

Base Information

Drug NameSCG162
Drug Alias NameNext-generationEBV TCR T-cell therapy (SCG Cell Therapy)SCG162SCG-162
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSCG Cell Therapy Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSCG Cell Therapy Pte Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A